Mylan and Biocon have announced the UK launch of Semglee – an approved biosimilar of reference medicine insulin glargine.
Semglee is a once-daily, long-acting basal insulin indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.
Around one in 17 people in the UK are thought to have diabetes, and the NHS currently spends around 10% of its entire budget on managing the disease, highlighting the huge drain on healthcare resources it presents.
Roche could soon see Tecentriq become part of the first immunotherapy combination approved to treat triple-negative breast cancer, after gaining a priority review from the FDA.
The company is seeking approval for first-line use of the drug in combination with Abraxane (chemotherapy) to treat unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in those who carry the PD-L1 protein.
The US drug regulator has said it will make its ruling by 12 March 2019, and will base its decision on findings the phase 3 Impassion130 study submitted by the company.
The results of that trial, which was presented at last month’s European Society for Medical Oncology (ESMO) Congress, showed that those taking the drug in combination with Abraxane had a significantly longer progression free survival (median of 1.7 months) over those taking Abraxane alone.
Wearable glucose monitors will be made available to tens of thousands more people with type 1 diabetes from April 2019, NHS England has announced.
Its decision comes after an investigation found patients in some areas of the country were being denied access to the device.
It reduces the need for finger-prick blood tests and helps people with diabetes to manage their condition.
Diabetes charities called the change of policy a huge step forward.
In England, around 300,000 people have type 1 diabetes.
An NHS project using social media has driven a 13% increase in first time attendances for breast screening in Stoke-on-Trent over four years.
Under the local initiative, information about screening was posted on Facebook community groups, in a bid to reduce anxiety surrounding breast examinations.
NHS Digital said the move empowered women to make appointments and also allowed them to communicate quickly and easily with health practitioners to ask questions about the screening process.
The initiative is part of NHS Digital’s Widening Digital Participation Programme, commissioned by NHS England, which aims to make digital health services and information accessible to everyone.
Across England attendances for breast screening are declining and most recent figures, from 2016-17, show the proportion of eligible women taking up breast screening in dropped to its lowest level in a decade.
A survey by the World Health Organization (WHO) has revealed huge variations in the use of antibiotics across the world, with certain countries recording very high levels of consumption.
The WHO Report on Surveillance of Antibiotic Consumption, published during World Antibiotic Awareness Week, gathered data on antibiotics use in 2015 across 65 countries and areas.
WHO said that the data could provide better insights into the patterns and volume of antibiotics use at national level, in turn supporting policies and regulations to optimise consumption.
A measure called defined daily dose (DDD), the average dose taken by a patient per day, was used to compare the medicine consumption between countries.
Pharmaceutical giant Sanofi – one of Europe’s largest suppliers of insulin – has been stockpiling drugs in the UK as fears mount over a no-deal Brexit.
The French company is preparing for Britain crashing out of the EU without a trade deal by building up its stocks of a range of medicines to 14 weeks’ supply from the current level of 10 weeks, because of uncertainty surrounding the Brexit negotiations, Sanofi said.
Hugo Fry, managing director of Sanofi UK said the company had “made arrangements for additional warehouse capacity in order to stockpile our products” and ensure patient safety.
Vital medical supplies risk are at risk unless transitional arrangements for the industry can be agreed, with the once distant prospect of no deal edging closer to reality as trade talks remain locked in stalemate.
Peanut allergy can be beaten with a treatment that slowly builds up tolerance, a large study shows.
None of nearly 500 four- to 17-year-olds from the US and Europe could tolerate even a 10th of a peanut dose.
But after taking tiny daily doses for a year, two-thirds could tolerate at least two whole peanuts.
Emily Pratt, six, told the BBC’s Today programme it had made a big difference. “I couldn’t have a birthday cake at parties and now I can,” she said.
She can now tolerate about seven peanuts, which means she can safely eat foods even if they may contain traces of peanut.
Treatment with testosterone could help tackle depression in men, according to a review of studies which found supplements of the hormone appear to improve mood.
About 100 million men around the world are thought to have depressive disorders, and almost 17% of men in the UK are thought to have symptoms of depression or anxiety.
However, evidence has been mixed on whether there is a link between testosterone levels and depression, and whether testosterone treatment could help with mood disorders in at least some cases. At present it is not recommended as a treatment for depression by the UK health watchdog, Nice.
Old age is the greatest risk factor for many diseases, including Alzheimer’s disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New Salk research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.
The study, which appeared in the journal Trends in Pharmacological Sciences, on November 13, 2018, was conducted in collaboration with Salk Senior Staff Scientist Pamela Maher, whose lab is in the Cellular Neurobiology department and who is the study’s senior author.
A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests. Scientists say the approach could be used to help doctors choose the best treatments for individual patients and predict which tumours are likely to respond to a particular therapy.
It could help target the use of immunotherapy – a new form of treatment that uses the body’s own defences to tackle cancer. This therapy has shown great promise in recent years, but identifying which patients will respond best is a challenge for doctors.
The new approach – based on gene analysis – makes it easier to spot the range of immune cells present in a tumour. These cells could help the body detect and kill cancer when activated by certain drugs, scientists say.
Traditional treatments such as radiology do not discriminate between cell types and attack both cancerous and healthy cells, often leading to side-effects.
Researchers at the University of Edinburgh analysed genes from anonymised medical databases of thousands of tumours to identify genes associated with immune cells.
This allowed them to quickly detect immune cells in a tumour based on their genetic code even when they were mixed in with harmful cancerous cells and normal cells.
They say that this resource – called ImSig – paints the best picture of tumours to date and will allow scientists to study how certain immune cell types affect cancer growth.
In future, this could help doctors decide which patients were most likely to respond to immunotherapy, experts say.
World Pharma News
Amgen announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).
AMGEVITA is authorized for the treatment of inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic evidence of AS; moderate-to-severe chronic plaque psoriasis; moderate-to-severe hidradenitis suppurativa; non-infectious intermediate, posterior and panuveitis; moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis. AMGEVITA is also authorized for the treatment of pediatric inflammatory diseases, including moderate-to-severe Crohn’s disease (ages six and older), severe chronic plaque psoriasis (ages four and older), enthesitis-related arthritis (ages six and older) and polyarticular juvenile idiopathic arthritis (ages two and older).
World Pharma News
We want to help your business grow – whether into new parts of the UK or on a global scale. Amber Road offers:
Fill in the form for more information. Alternatively, you can meet the team here or give us a call on +44 (0) 333 444 2284